Literature DB >> 2748873

Common side effects associated with monoamine oxidase inhibitors.

R A Remick1, C Froese, F D Keller.   

Abstract

There is relatively little documentation on the common side effects associated with monoamine oxidase inhibitors (MAOI) and their frequency of occurrence. A retrospective chart review of patient records in a Mood Disorders Service was completed. Side effects of patients receiving phenelzine (N = 42) and tranylcypromine (N = 19) were rated as mild (resulting in no change in treatment), moderate (some modification in treatment plan necessary), and severe (definite change in treatment plan or drug discontinuation due to MAOI side effect). A total of 35 reports of side effects were noted in 15 of 19 tranylcypromine patients (1.84 per patients) and a total of 125 side effect reports were noted in 39 of 42 phenelzine patients (2.98 per patient). Only two severe tranylcypromine side effects occurred (resulting in drug cessation for one of these patients - hypotension), while 9 severe reactions occurred with phenelzine, resulting in drug discontinuation in 6 of these patients. The side effects for tranylcypromine and the number of reports were insomnia (N = 10), sedation (N = 8), hypotension (N = 5), sexual dysfunction (N = 3), hypomania (N = 3), weight gain/edema (N = 2), hypertensive episode (N = 2), and myoclonic jerking (N = 2). The number of reports of phenelzine side effects were insomnia (N = 26), hypomania/mania (N = 27; most common reason for drug cessation - 4), hypotension (N = 16; three cases considered severe), weight gain/edema (N = 15), sedation (N = 15), sexual dysfunction (N = 13), hypertensive episode (N = 6), and myoclonic jerking (N = 7).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2748873     DOI: 10.1016/0278-5846(89)90137-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  Monoamine oxidase inhibitors: clinical review.

Authors:  R A Remick; C Froese
Journal:  Can Fam Physician       Date:  1990-06       Impact factor: 3.275

Review 2.  Drug-induced male sexual dysfunction. An update.

Authors:  G B Brock; T F Lue
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

3.  Associations of a regulatory polymorphism of monoamine oxidase-A gene promoter (MAOA-uVNTR) with symptoms of depression and sleep quality.

Authors:  Beverly H Brummett; Andrew D Krystal; Ilene C Siegler; Cynthia Kuhn; Richard S Surwit; Stephan Züchner; Allison Ashley-Koch; John C Barefoot; Redford B Williams
Journal:  Psychosom Med       Date:  2007-06       Impact factor: 4.312

4.  MAO-inhibitors in Parkinson's Disease.

Authors:  Peter Riederer; Gerd Laux
Journal:  Exp Neurobiol       Date:  2011-03-31       Impact factor: 3.261

5.  Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model.

Authors:  Jing Huang; Fangkun Liu; Hui Tang; Haishan Wu; Lehua Li; Renrong Wu; Jingping Zhao; Ying Wu; Zhixiong Liu; Jindong Chen
Journal:  Front Neurol       Date:  2017-12-07       Impact factor: 4.003

6.  OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females.

Authors:  Mitchell F Brin; Suresh Durgam; Arlene Lum; Lynn James; Jeen Liu; Michael E Thase; Armin Szegedi
Journal:  Int Clin Psychopharmacol       Date:  2020-01       Impact factor: 2.023

7.  A review of vilazodone, serotonin, and major depressive disorder.

Authors:  Kerri A Pierz; Michael E Thase
Journal:  Prim Care Companion CNS Disord       Date:  2014-01-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.